protein receptor that down regulates the immune system when bound to antigen presenting cells. Ipilimumab selectively binds to CTLA-4 inhibiting the immune tolerance to tumour cells and has recently ... sequelae are…
Background: Ipilimumab is a fully humanized monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). In 2010, ipilimumab became the first systemic therapy to improve the overall survival…
which provides rationale for immunotherapy in MCC. This manuscript reports the first application of ipilimumab in the treatment of a MCC patient. In this case, combination treatment of a stage ... patient with…
November 2018 the European Medicines Agency approved Nivolumab plus Ipilimumab as first-line therapy in intermediate- or poor-risk Advanced Renal Cell Carcinoma (aRCC) patients. This made it mandatory ... volume centres…
result, Immune-Related Adverse Effects (irAE) can occur [2]. We present a case of ipilimumab and nivolumab-induced pancreatitis and hepatitis in a woman who was treated for malignant melanoma ... After two cycles of…
clinical course of a patient with metastatic melanoma who received combination therapy with ipilimumab, a CTLA-4 checkpoint inhibitor, and an Indoleamine 2,3-Dioxygenase (IDO)-silenced Dendritic Cell
reverse phase liquid chromatographic method was developed for the simultaneous estimation of Nivolumab and Ipilimumab in bulk and tablet dosage form. A RP Inertsil ODS, having dimensions
metastasis of RCC to the lungs was found, and combination therapy with nivolumab and ipilimumab was started; however, after 21 days liver enzyme tests showed abnormalities. Liver biopsy showed pathological
have two therapies that have demonstrated survival benefit in Phase III clinical trials – one, ipilimumab, a monoclonal antibody against CTLA-4, a checkpoint inhibitor, and the other, Sipuleucel ... autologous-based…
reported frequency of ipilimumab-induced hypophysitis (IIH), a cytotoxic T-lymphocyte antigen 4 antibody, ranges from 0 to 17%, in contrast to the rarity of idiopathic autoimmune hypophysitis that ... nine million…
meta-analysis, dabrafenib and trametinib were compared directly versus dacarbazine (DTIC) and indirectly versus ipilimumab plus DTIC, temozolomide, and vemurafenib. A Rank Preserving Structural Failure Time Method was…
real-world data from our single-center experience using a combination of nivolumab and ipilimumab as neoadjuvant therapy in patients with DMMR stage III colon cancer. Our findings contribute
report a patient with a known history of metastatic melanoma undergoing treatment with Ipilimumab + Nivolumab who developed an RTA and was successfully treated with stress dose steroids and sodium bicarbonate
TRAEs, and 6 had a history of thyroidectomy (excluded). At least one dose of ipilimumab and/or nivolumab or pembrolizumab was administered. Post- Immune checkpoint blockade therapy TRAEs were classified ... days…
Based on remarkable and sustained antitumor activity, the anti-CTLA-4 antibody ipilimumab, and anti-PD1 antibodies nivolumab and pembrolizumab have been approved for treatment of advanced melanoma. As checkpoint
approval of vemurafenib, a first-in-class inhibitor of BRAF V600E mutant melanoma, and ipilimumab, a first-in-class CTLA-4 inhibitor, we now have two agents that improve survival
augment the immune response, combination therapies of therapeutic vaccines with checkpoint inhibitors such as ipilimumab are currently tested in clinical studies. Ipilimumab is an antibody that blocks the immune…